{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:55:51Z","timestamp":1785210951799,"version":"3.55.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12265-024-10587-7","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:00:34Z","timestamp":1736780434000},"page":"424-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis"],"prefix":"10.1007","volume":"18","author":[{"given":"Bin","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3745-8334","authenticated-orcid":false,"given":"Kaisen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"10587_CR1","unstructured":"World Health Organization. Cardiovascular diseases (cvds). Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds), 2021 accessed January 22, 2023"},{"issue":"18","key":"10587_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"16","key":"10587_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated ldl cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"6213","key":"10587_CR4","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. The new frontier of genome engineering with crispr-cas9. Science. 2014;346(6213):1258096. https:\/\/doi.org\/10.1126\/science.1258096.","journal-title":"Science"},{"issue":"8","key":"10587_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver A, Gersbach CA. The next generation of crispr-cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490\u2013507. https:\/\/doi.org\/10.1038\/s41580-019-0131-5.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10587_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","volume":"25","author":"TA Lagace","year":"2014","unstructured":"Lagace TA. Pcsk9 and ldlr degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387\u201393. https:\/\/doi.org\/10.1097\/MOL.0000000000000114.","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10587_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in pcsk9, low ldl, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"issue":"5","key":"10587_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","volume":"65","author":"TP Leren","year":"2004","unstructured":"Leren TP. Mutations in the pcsk9 gene in norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65(5):419\u201322. https:\/\/doi.org\/10.1111\/j.0009-9163.2004.0238.x.","journal-title":"Clin Genet"},{"issue":"22","key":"10587_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"7859","key":"10587_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo crispr base editing of pcsk9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334. https:\/\/doi.org\/10.1038\/s41586-021-03534-y.","journal-title":"Nature"},{"issue":"5","key":"10587_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","volume":"115","author":"Q Ding","year":"2014","unstructured":"Ding Q, Strong A, Patel KM, et al. Permanent alteration of pcsk9 with in vivo crispr-cas9 genome editing. Circ Res. 2014;115(5):488\u201392. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.304351.","journal-title":"Circ Res"},{"issue":"8","key":"10587_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl T, Dennis MK, Lin PJ, et al. In vivo adenine base editing of pcsk9 in macaques reduces ldl cholesterol levels. Nat Biotechnol. 2021;39(8):949\u201357. https:\/\/doi.org\/10.1038\/s41587-021-00933-4.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10587_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/cvr\/cvac048","volume":"119","author":"K Musunuru","year":"2023","unstructured":"Musunuru K. Crispr and cardiovascular diseases. Cardiovasc Res. 2023;119(1):79\u201393. https:\/\/doi.org\/10.1093\/cvr\/cvac048.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10587_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","volume":"130","author":"S Rashid","year":"2014","unstructured":"Rashid S, Tavori H, Brown PE, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein b lipoproteins through both low-density lipoprotein receptor-dependent and-independent mechanisms. Circulation. 2014;130(5):431\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006720.","journal-title":"Circulation"},{"issue":"24","key":"10587_CR15","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","volume":"127","author":"H Tavori","year":"2013","unstructured":"Tavori H, Fan D, Blakemore JL, et al. Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127(24):2403\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001592.","journal-title":"Circulation"},{"issue":"7","key":"10587_CR16","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma pcsk9 levels. The Journal of Clinical Endocrinology & Metabolism. 2009;94(7):2537\u201343. https:\/\/doi.org\/10.1210\/jc.2009-0141.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10587_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"B Cariou","year":"2011","unstructured":"Cariou B, Le May C, Costet P. Clinical aspects of pcsk9. Atherosclerosis. 2011;216(2):258\u201365. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.018.","journal-title":"Atherosclerosis"},{"issue":"6","key":"10587_CR18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1194\/jlr.P065334","volume":"57","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al. Pcsk9 inhibition-mediated reduction in lp(a) with evolocumab: an analysis of 10 clinical trials and the ldl receptor\u2019s role. J Lipid Res. 2016;57(6):1086\u201396. https:\/\/doi.org\/10.1194\/jlr.P065334.","journal-title":"J Lipid Res"},{"issue":"1","key":"10587_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","volume":"119","author":"H Tavori","year":"2016","unstructured":"Tavori H, Christian D, Minnier J, et al. Pcsk9 association with lipoprotein (a). Circ Res. 2016;119(1):29\u201335. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308811.","journal-title":"Circ Res"},{"key":"10587_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"JM Cheng","year":"2016","unstructured":"Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. Pcsk9 in relation to coronary plaque inflammation: Results of the atheroremo-ivus study. Atherosclerosis. 2016;248:117\u201322. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.010.","journal-title":"Atherosclerosis"},{"issue":"7","key":"10587_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","volume":"125","author":"M Denis","year":"2012","unstructured":"Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125(7):894\u2013901. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.057406.","journal-title":"Circulation"},{"issue":"11","key":"10587_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCRESAHA.121.320056","volume":"131","author":"S Katsuki","year":"2022","unstructured":"Katsuki S, Jha PK, Lupieri A, et al. Proprotein convertase subtilisin\/kexin 9 (pcsk9) promotes macrophage activation via ldl receptor-independent mechanisms. Circ Res. 2022;131(11):873\u201389. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.320056.","journal-title":"Circ Res"},{"issue":"1","key":"10587_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20425-x","volume":"8","author":"C Ricci","year":"2018","unstructured":"Ricci C, Ruscica M, Camera M, et al. Pcsk9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-20425-x.","journal-title":"Sci Rep"},{"issue":"10","key":"10587_CR24","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S Kuhnast","year":"2014","unstructured":"Kuhnast S, van der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103\u201312. https:\/\/doi.org\/10.1194\/jlr.M051326.","journal-title":"J Lipid Res"},{"issue":"9","key":"10587_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/ars.2014.6054","volume":"22","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X, et al. Hemodynamic shear stress via ros modulates pcsk9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2015;22(9):760\u201371. https:\/\/doi.org\/10.1089\/ars.2014.6054.","journal-title":"Antioxid Redox Signal"},{"key":"10587_CR26","doi-asserted-by":"publisher","first-page":"1126823","DOI":"10.3389\/fimmu.2023.1126823","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Interactions between pcsk9 and nlrp3 inflammasome signaling in atherosclerosis. Front Immunol. 2023;14:1126823. https:\/\/doi.org\/10.3389\/fimmu.2023.1126823.","journal-title":"Front Immunol"},{"issue":"1","key":"10587_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10753-022-01715-z","volume":"46","author":"L Huang","year":"2023","unstructured":"Huang L, Li Y, Cheng Z, et al. Pcsk9 promotes endothelial dysfunction during sepsis via the tlr4\/myd88\/nf-$$\\kappa $$b and nlrp3 pathways. Inflammation. 2023;46(1):115\u201328. https:\/\/doi.org\/10.1007\/s10753-022-01715-z.","journal-title":"Inflammation"},{"key":"10587_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","volume":"227","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Kolodziejczak M, Winter MP, et al. Association of pcsk9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the pcsk9-react study. Int J Cardiol. 2015;227:644\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.084.","journal-title":"Int J Cardiol"},{"issue":"1","key":"10587_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","volume":"143","author":"Z Qi","year":"2021","unstructured":"Qi Z, Hu L, Zhang J, et al. Pcsk9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet cd36. Circulation. 2021;143(1):45\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046290.","journal-title":"Circulation"},{"key":"10587_CR30","doi-asserted-by":"publisher","unstructured":"Agarwal H, Tinsley B, Sarecha AK, et al. Rap1 in the context of pcsk9, atherosclerosis, and diabetes. Curr Atheroscler Rep. 2023;25(12):931\u20137. https:\/\/doi.org\/10.1007\/s11883-023-01162-7.https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01162-7","DOI":"10.1007\/s11883-023-01162-7"},{"key":"10587_CR31","doi-asserted-by":"publisher","unstructured":"Pavlakou P, Liberopoulos E, Dounousi E, et al. Pcsk9 in chronic kidney disease. Int Urol Nephrol. 2017;49(6):1015\u201324. https:\/\/doi.org\/10.1007\/s11255-017-1505-2. https:\/\/link.springer.com\/article\/10.1007\/s11255-017-1505-2","DOI":"10.1007\/s11255-017-1505-2"},{"issue":"5","key":"10587_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367\u201383. https:\/\/doi.org\/10.1038\/nrd3699.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10587_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.tibtech.2020.10.010","volume":"39","author":"CMA Zeballos","year":"2021","unstructured":"Zeballos CMA, Gaj T. Next-generation crispr technologies and their applications in gene and cell therapy. Trends Biotechnol. 2021;39(7):692\u2013705. https:\/\/doi.org\/10.1016\/j.tibtech.2020.10.010.","journal-title":"Trends Biotechnol"},{"key":"10587_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA. Crispr-cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505\u201329. https:\/\/doi.org\/10.1146\/annurev-biophys-062215-010822.","journal-title":"Annu Rev Biophys"},{"key":"10587_CR35","doi-asserted-by":"publisher","unstructured":"Jinek M, East A, Cheng A, et al. Rna-programmed genome editing in human cells. eLife 2013;2:e00471. https:\/\/doi.org\/10.7554\/eLife.00471","DOI":"10.7554\/eLife.00471"},{"issue":"12","key":"10587_CR36","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/mtm.2016.34","volume":"29","author":"S Kathiresan","year":"2023","unstructured":"Kathiresan S, et al. Clinical development of gene editing therapeutics. Nat Med. 2023;29(12):2789\u2013801. https:\/\/doi.org\/10.1038\/mtm.2016.34.","journal-title":"Nat Med"},{"issue":"5819","key":"10587_CR37","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, et al. Crispr provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709\u201312. https:\/\/doi.org\/10.1126\/science.1138140.","journal-title":"Science"},{"issue":"6096","key":"10587_CR38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-rna-guided dna endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321. https:\/\/doi.org\/10.1126\/science.1225829.","journal-title":"Science"},{"issue":"11","key":"10587_CR39","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, et al. Genome engineering using the crispr-cas9 system. Nat Protoc. 2013;8(11):2281\u2013308. https:\/\/doi.org\/10.1038\/nprot.2013.143.","journal-title":"Nat Protoc"},{"issue":"6","key":"10587_CR40","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of crispr-cas9 for genome engineering. Cell. 2014;157(6):1262\u201378. https:\/\/doi.org\/10.1016\/j.cell.2014.05.010.","journal-title":"Cell"},{"issue":"7546","key":"10587_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA, Cong L, Yan WX, et al. In vivo genome editing using staphylococcus aureus cas9. Nature. 2015;520(7546):186\u201391. https:\/\/doi.org\/10.1038\/nature14299.","journal-title":"Nature"},{"issue":"7","key":"10587_CR42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with crispr-cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824\u201344. https:\/\/doi.org\/10.1038\/s41587-020-0561-9.","journal-title":"Nat Biotechnol"},{"key":"10587_CR43","doi-asserted-by":"publisher","unstructured":"Dagdas YS, Chen JS, Sternberg SH, et al. A conformational checkpoint between dna binding and cleavage by crispr-cas9. Sci Adv 2017;3(8):eaao0027. https:\/\/doi.org\/10.1126\/sciadv.aao0027","DOI":"10.1126\/sciadv.aao0027"},{"issue":"3","key":"10587_CR44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, et al. The evolving future of pcsk9 inhibitors. J Am Coll Cardiol. 2018;72(3):314\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.054.","journal-title":"J Am Coll Cardiol"},{"key":"10587_CR45","doi-asserted-by":"publisher","first-page":"44624","DOI":"10.1038\/srep44624","volume":"7","author":"KE Jarrett","year":"2018","unstructured":"Jarrett KE, Lee CM, Yeh YH, et al. Somatic genome editing with crispr\/cas9 generates and corrects a metabolic disease. Sci Rep. 2018;7:44624. https:\/\/doi.org\/10.1038\/srep44624.","journal-title":"Sci Rep"},{"issue":"7723","key":"10587_CR46","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-018-0500-9","volume":"561","author":"P Akcakaya","year":"2018","unstructured":"Akcakaya P, Bobbin ML, Guo JA, et al. In vivo crispr editing with no detectable genome-wide off-target mutations. Nature. 2018;561(7723):416\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0500-9.","journal-title":"Nature"},{"issue":"6","key":"10587_CR47","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","volume":"28","author":"A Li","year":"2020","unstructured":"Li A, Tanner MR, Lee CM, et al. Aav-crispr gene editing is negated by pre-existing immunity to cas9. Mol Ther. 2020;28(6):1432\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.017.","journal-title":"Mol Ther"},{"issue":"1","key":"10587_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05843-9","volume":"9","author":"JM Crudele","year":"2018","unstructured":"Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for crispr gene editing therapies. Nat Commun. 2018;9(1):1\u20133. https:\/\/doi.org\/10.1038\/s41467-018-05843-9.","journal-title":"Nat Commun"},{"issue":"7","key":"10587_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla SK, Persson J, et al. Crispr-cas9 genome editing induces a p53-mediated dna damage response. Nat Med. 2018;24(7):927\u201330. https:\/\/doi.org\/10.1038\/s41591-018-0049-z.","journal-title":"Nat Med"},{"issue":"1","key":"10587_CR50","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang D, Zhang F, Gao G. Crispr-based therapeutic genome editing: strategies and in vivo delivery by aav vectors. Cell. 2020;181(1):136\u201350. https:\/\/doi.org\/10.1016\/j.cell.2020.03.023.","journal-title":"Cell"},{"issue":"7","key":"10587_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3107","volume":"21","author":"X Xu","year":"2019","unstructured":"Xu X, Wan T, Xin H, et al. Delivery of crispr\/cas9 for therapeutic genome editing. J Gene Med. 2019;21(7): e3107. https:\/\/doi.org\/10.1002\/jgm.3107.","journal-title":"J Gene Med"},{"issue":"7","key":"10587_CR52","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli NM, Lam DK, Rees HA, et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol. 2020;38(7):892\u2013900. https:\/\/doi.org\/10.1038\/s41587-020-0491-6.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10587_CR53","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR, et al. A high-fidelity cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24(8):1216\u201324. https:\/\/doi.org\/10.1038\/s41591-018-0137-0.","journal-title":"Nat Med"},{"issue":"11","key":"10587_CR54","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1016\/j.apsb.2022.08.013","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Li C, Wang Y, et al. Smart drug delivery systems for precise cancer therapy. Acta Pharmaceutica Sinica B. 2022;12(11):4098\u2013121. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.013.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"4","key":"10587_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, et al. Adeno-associated virus (aav) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334. https:\/\/doi.org\/10.1007\/s40259-017-0234-5.","journal-title":"BioDrugs"},{"issue":"12","key":"10587_CR56","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/hum.2008.123","volume":"19","author":"LT Bish","year":"2008","unstructured":"Bish LT, Morine K, Sleeper MM, et al. Adeno-associated virus (aav) serotype 9 provides global cardiac gene transfer superior to aav1, aav6, aav7, and aav8 in the mouse and rat. Hum Gene Ther. 2008;19(12):1359\u201368. https:\/\/doi.org\/10.1089\/hum.2008.123.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10587_CR57","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78(12):6381\u20138. https:\/\/doi.org\/10.1128\/JVI.78.12.6381-6388.2004.","journal-title":"J Virol"},{"issue":"7546","key":"10587_CR58","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"F Ran","year":"2015","unstructured":"Ran F, Cong L, Yan W, et al. In vivo genome editing using staphylococcus aureus cas9. Nature. 2015;520(7546):186\u201391. https:\/\/doi.org\/10.1038\/nature14299.","journal-title":"Nature"},{"key":"10587_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S429411","volume":"18","author":"AM Mengstie","year":"2024","unstructured":"Mengstie AM, Azezew TM, Dejenie AT, et al. Recent advancements in reducing the off-target effect of crispr-cas9 genome editing. Biologics. 2024;18:21\u20138. https:\/\/doi.org\/10.2147\/BTT.S429411.","journal-title":"Biologics"},{"issue":"7","key":"10587_CR60","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529\u201341. https:\/\/doi.org\/10.1038\/s41375-018-0106-0.","journal-title":"Leukemia"},{"issue":"6166","key":"10587_CR61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale crispr-cas9 knockout screening in human cells. Science. 2014;343(6166):84\u20137. https:\/\/doi.org\/10.1126\/science.1247005.","journal-title":"Science"},{"issue":"7667","key":"10587_CR62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature23451","volume":"548","author":"J Joung","year":"2017","unstructured":"Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a lncrna locus regulating a gene neighbourhood. Nature. 2017;548(7667):343\u20136. https:\/\/doi.org\/10.1038\/nature23451.","journal-title":"Nature"},{"issue":"1","key":"10587_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17180-w","volume":"7","author":"E Ehrke-Schulz","year":"2017","unstructured":"Ehrke-Schulz E, Schiwon M, Leitner T, et al. Crispr\/cas9 delivery with one single adenoviral vector devoid of all viral genes. Sci Rep. 2017;7(1):1\u201313. https:\/\/doi.org\/10.1038\/s41598-017-17180-w.","journal-title":"Sci Rep"},{"issue":"3","key":"10587_CR64","doi-asserted-by":"publisher","first-page":"e01885","DOI":"10.1128\/JVI.01885-18","volume":"93","author":"C Bressy","year":"2019","unstructured":"Bressy C, Droby GN, Maldonado BD, et al. Cell cycle arrest in g2\/m phase enhances replication of interferon-sensitive cytoplasmic rna viruses via inhibition of antiviral gene expression. J Virol. 2019;93(3):e01885-18. https:\/\/doi.org\/10.1128\/JVI.01885-18.","journal-title":"J Virol"},{"issue":"4","key":"10587_CR65","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1093\/nar\/gkt1163","volume":"42","author":"Y Cai","year":"2014","unstructured":"Cai Y, Bak RO, Krogh LB, et al. Dna transposition by protein transduction of the piggybac transposase from lentiviral gag precursors. Nucleic Acids Res. 2014;42(4):e28\u2013e28. https:\/\/doi.org\/10.1093\/nar\/gkt1163.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10587_CR66","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WS Wold","year":"2013","unstructured":"Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Current Gene Therapy. 2013;13(6):421\u201333. https:\/\/doi.org\/10.2174\/1566523213666131125095046.","journal-title":"Current Gene Therapy"},{"issue":"3","key":"10587_CR67","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","volume":"37","author":"Y Rui","year":"2019","unstructured":"Rui Y, Wilson DR, Green JJ. Non-viral delivery to enable genome editing. Trends Biotechnol. 2019;37(3):281\u201393. https:\/\/doi.org\/10.1016\/j.tibtech.2018.08.010.","journal-title":"Trends Biotechnol"},{"issue":"10","key":"10587_CR68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","volume":"14","author":"G Chen","year":"2019","unstructured":"Chen G, Abdeen AA, Wang Y, et al. A biodegradable nanocapsule delivers a cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019;14(10):974\u201380. https:\/\/doi.org\/10.1038\/s41565-019-0539-2.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"10587_CR69","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin H, Song CQ, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of crispr system components in vivo. Nat Biotechnol. 2016;34(3):328\u201333. https:\/\/doi.org\/10.1038\/nbt.3471.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10587_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, et al. Selective organ targeting (sort) nanoparticles for tissue-specific mrna delivery and crispr-cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"10587_CR71","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/wnan.1228","volume":"5","author":"S H\u00f6bel","year":"2013","unstructured":"H\u00f6bel S, Aigner A. Polyethylenimines for sirna and mirna delivery in vivo. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2013;5(5):484\u2013501. https:\/\/doi.org\/10.1002\/wnan.1228.","journal-title":"Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology"},{"key":"10587_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"266","author":"C Liu","year":"2017","unstructured":"Liu C, Zhang L, Liu H, et al. Delivery strategies of the crispr-cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17\u201326. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.012.","journal-title":"J Control Release"},{"key":"10587_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.biomaterials.2017.09.015","volume":"147","author":"C Liang","year":"2017","unstructured":"Liang C, Li F, Wang L, et al. Tumor cell-targeted delivery of crispr\/cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of vegfa in osteosarcoma. Biomaterials. 2017;147:68\u201385. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.09.015.","journal-title":"Biomaterials"},{"issue":"6","key":"10587_CR74","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/anie.201708689","volume":"57","author":"P Wang","year":"2018","unstructured":"Wang P, Zhang L, Zheng W, et al. Thermo-triggered release of crispr-cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy. Angew Chem Int Ed. 2018;57(6):1491\u20136. https:\/\/doi.org\/10.1002\/anie.201708689.","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"10587_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1021\/acsnano.6b04261","volume":"11","author":"L Li","year":"2017","unstructured":"Li L, Song L, Liu X, et al. Artificial virus delivers crispr-cas9 system for genome editing of cells in mice. ACS Nano. 2017;11(1):95\u2013111. https:\/\/doi.org\/10.1021\/acsnano.6b04261.","journal-title":"ACS Nano"},{"issue":"7","key":"10587_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","volume":"2","author":"B Lee","year":"2018","unstructured":"Lee B, Lee K, Panda S, et al. Nanoparticle delivery of crispr into the brain rescues a mouse model of fragile x syndrome from exaggerated repetitive behaviours. Nat Biomed Eng. 2018;2(7):497\u2013507. https:\/\/doi.org\/10.1038\/s41551-018-0252-8.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10587_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/btm2.10049","volume":"2","author":"MJ Rohovie","year":"2017","unstructured":"Rohovie MJ, Nagasawa M, Swartz JR. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng & Transl Med. 2017;2(1):43\u201357. https:\/\/doi.org\/10.1002\/btm2.10049.","journal-title":"Bioeng & Transl Med"},{"issue":"1","key":"10587_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07845-z","volume":"10","author":"PE Mangeot","year":"2019","unstructured":"Mangeot PE, Risson V, Fusil F, et al. Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with cas9-sgrna ribonucleoproteins. Nat Commun. 2019;10(1):1\u201315. https:\/\/doi.org\/10.1038\/s41467-018-07845-z.","journal-title":"Nat Commun"},{"issue":"15","key":"10587_CR79","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1016\/j.celrep.2021.109207","volume":"184","author":"JR Hamilton","year":"2021","unstructured":"Hamilton JR, Tsuchida CA, Nguyen DN, et al. Targeted delivery of crispr-cas9 and transgenes enables complex immune cell engineering. Cell. 2021;184(15):4166\u201379. https:\/\/doi.org\/10.1016\/j.celrep.2021.109207.","journal-title":"Cell"},{"issue":"1","key":"10587_CR80","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cobme.2018.08.003","volume":"28","author":"Y Cai","year":"2020","unstructured":"Cai Y, Liang P, Tang Q, et al. Adeno-associated virus-mediated in vivo genome editing via crispr\/cas9 system. Mol Ther. 2020;28(1):87\u201395. https:\/\/doi.org\/10.1016\/j.cobme.2018.08.003.","journal-title":"Mol Ther"},{"issue":"4","key":"10587_CR81","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38(4):406\u201324. https:\/\/doi.org\/10.1016\/j.tips.2017.01.003.","journal-title":"Trends Pharmacol Sci"},{"key":"10587_CR82","doi-asserted-by":"crossref","unstructured":"Lira C, Correia EM, Bonamino MH, et al. Cell-penetrating peptides and crispr-cas9: A combined strategy for human genetic disease therapy. Human Gene Therapy 2024;35(19-20):781\u2013797. https:\/\/api.semanticscholar.org\/CorpusID:272653102","DOI":"10.1089\/hum.2024.020"},{"issue":"6","key":"10587_CR83","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1101\/gr.171264.113","volume":"24","author":"S Ramakrishna","year":"2014","unstructured":"Ramakrishna S, Dad AB, Beloor J, et al. Gene disruption by cell-penetrating peptide-mediated delivery of cas9 protein and guide rna. Genome Res. 2014;24(6):1020\u20137. https:\/\/doi.org\/10.1101\/gr.171264.113.","journal-title":"Genome Res"},{"issue":"19","key":"10587_CR84","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1073\/pnas.1712963115","volume":"115","author":"HX Wang","year":"2018","unstructured":"Wang HX, Song Z, Lao YH, et al. Nonviral gene editing via crispr\/cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. Proceedings of the National Academy of Sciences. 2018;115(19):4903\u20138. https:\/\/doi.org\/10.1073\/pnas.1712963115.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"10587_CR85","doi-asserted-by":"publisher","first-page":"1700175","DOI":"10.1002\/advs.201700175","volume":"4","author":"P Wang","year":"2017","unstructured":"Wang P, Zhang L, Xie Y, et al. Genome editing for cancer therapy: delivery of cas9 protein\/sgrna plasmid via a gold nanocluster\/lipid core-shell nanocarrier. Adv Sci. 2017;4(11):1700175. https:\/\/doi.org\/10.1002\/advs.201700175.","journal-title":"Adv Sci"},{"key":"10587_CR86","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","volume":"219","author":"EV Batrakova","year":"2015","unstructured":"Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396\u2013405. https:\/\/doi.org\/10.1016\/j.jconrel.2015.07.030.","journal-title":"J Control Release"},{"issue":"4","key":"10587_CR87","doi-asserted-by":"publisher","first-page":"1700611","DOI":"10.1002\/advs.201700611","volume":"5","author":"Y Lin","year":"2018","unstructured":"Lin Y, Wu J, Gu W, et al. Exosome-liposome hybrid nanoparticles deliver crispr\/cas9 system in mscs. Adv Sci. 2018;5(4):1700611. https:\/\/doi.org\/10.1002\/advs.201700611.","journal-title":"Adv Sci"},{"issue":"1","key":"10587_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-04791-8","volume":"9","author":"WM Usman","year":"2018","unstructured":"Usman WM, Pham TC, Kwok YY, et al. Efficient rna drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):1\u201315. https:\/\/doi.org\/10.1038\/s41467-018-04791-8.","journal-title":"Nat Commun"},{"issue":"7794","key":"10587_CR89","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229\u201336. https:\/\/doi.org\/10.1038\/s41586-020-1978-5.","journal-title":"Nature"},{"issue":"2","key":"10587_CR90","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","volume":"10","author":"T Horie","year":"2024","unstructured":"Horie T, Ono K. Verve-101: A promising crispr-based gene editing therapy that reduces ldl-c and pcsk9 levels in hefh patients. Eur Heart J - Cardiovascular Pharmacotherapy. 2024;10(2):89\u201390. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad103.","journal-title":"Eur Heart J - Cardiovascular Pharmacotherapy"},{"issue":"2","key":"10587_CR91","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ehjcvp\/pvad095","volume":"10","author":"BS Lewis","year":"2023","unstructured":"Lewis BS. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA. Eur Heart J - Cardiovascular Pharmacotherapy. 2023;10(2):87\u20138. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad095.","journal-title":"Eur Heart J - Cardiovascular Pharmacotherapy"},{"issue":"8","key":"10587_CR92","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","volume":"33","author":"AJ Hooper","year":"2024","unstructured":"Hooper AJ, Tang XL, Burnett JR. Verve-101, a crispr base-editing therapy designed to permanently inactivate hepatic pcsk9 and reduce ldl-cholesterol. Expert Opinion on Investigational Drugs. 2024;33(8):753\u20136. https:\/\/doi.org\/10.1080\/13543784.2024.2369747.","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"9","key":"10587_CR93","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","volume":"45","author":"\u00c9 Gobeil","year":"2024","unstructured":"Gobeil \u00c9, Bourgault J, Mitchell PL, et al. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. Eur Heart J. 2024;45(9):707\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehad845.","journal-title":"Eur Heart J"},{"issue":"2","key":"10587_CR94","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner DL, Amini L, Wendering DJ, et al. High prevalence of streptococcus pyogenes cas9-reactive t cells within the adult human population. Nat Med. 2019;25(2):242\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0204-6.","journal-title":"Nat Med"},{"key":"10587_CR95","unstructured":"European Medicines Agency. ICH Guideline S12 on Nonclinical Biodistribution Considerations for Gene Therapy Products. 2024. https:\/\/www.ema.europa.eu\/en\/ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-step-2b-scientific-guideline, accessed: 2024-10-21"},{"issue":"4","key":"10587_CR96","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584\u201391. https:\/\/doi.org\/10.1038\/s41588-019-0379-x.","journal-title":"Nat Genet"},{"key":"10587_CR97","unstructured":"U.S. Food and Drug Administration. Chemistry, manufacturing, and control (cmc) information for human gene therapy investigational new drug applications. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug, accessed: 2024-10-21"},{"key":"10587_CR98","volume-title":"Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research. WHO, Geneva: Tech. rep; 2022."},{"issue":"1","key":"10587_CR99","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13023-024-03249-z","volume":"19","author":"H Ossandon","year":"2024","unstructured":"Ossandon H, Armijo N, Vargas C, et al. Challenges for gene therapy in the financial sustainability of health systems: a scoping review. Orphanet Journal of Rare Diseases. 2024;19(1):243. https:\/\/doi.org\/10.1186\/s13023-024-03249-z.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"9","key":"10587_CR100","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by crispr-cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822\u20136. https:\/\/doi.org\/10.1038\/nbt.2623.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10587_CR101","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by crispr-cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371. https:\/\/doi.org\/10.1038\/nbt.4192.","journal-title":"Nat Biotechnol"},{"issue":"6268","key":"10587_CR102","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered cas9 nucleases with improved specificity. Science. 2016;351(6268):84\u20138. https:\/\/doi.org\/10.1126\/science.aad5227.","journal-title":"Science"},{"issue":"1","key":"10587_CR103","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to aav vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23\u201336. https:\/\/doi.org\/10.1182\/blood-2013-01-306647.","journal-title":"Blood"},{"issue":"1","key":"10587_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09693-x","volume":"10","author":"SR Ferdosi","year":"2019","unstructured":"Ferdosi SR, Ewaisha R, Moghadam F, et al. Multifunctional crispr-cas9 with engineered immunosilenced human t cell epitopes. Nat Commun. 2019;10(1):1\u201311. https:\/\/doi.org\/10.1038\/s41467-019-09693-x.","journal-title":"Nat Commun"},{"issue":"1","key":"10587_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-018-1515-0","volume":"19","author":"R Ibraheim","year":"2018","unstructured":"Ibraheim R, Song C, Mir A, et al. All-in-one adeno-associated virus delivery and genome editing by neisseria meningitidis cas9 in vivo. Genome Biol. 2018;19(1):1\u20139. https:\/\/doi.org\/10.1186\/s13059-018-1515-0.","journal-title":"Genome Biol"},{"key":"10587_CR106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63\u201389. https:\/\/doi.org\/10.1146\/annurev-bioeng-071813-104938.","journal-title":"Annu Rev Biomed Eng"},{"issue":"6","key":"10587_CR107","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","volume":"38","author":"X Yu","year":"2016","unstructured":"Yu X, Liang X, Xie H, et al. Improved delivery of cas9 protein\/grna complexes using lipofectamine crisprmax. Biotechnol Lett. 2016;38(6):919\u201329. https:\/\/doi.org\/10.1007\/s10529-016-2064-9.","journal-title":"Biotechnol Lett"},{"issue":"2","key":"10587_CR108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","volume":"25","author":"GX Ruan","year":"2017","unstructured":"Ruan GX, Barry E, Yu D, et al. Crispr\/cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10. Mol Ther. 2017;25(2):331\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2016.12.006.","journal-title":"Mol Ther"},{"issue":"2","key":"10587_CR109","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder ML, Stefanidakis M, Wilson CJ, et al. Development of a gene-editing approach to restore vision loss in leber congenital amaurosis type 10. Nat Med. 2019;25(2):229\u201333. https:\/\/doi.org\/10.1038\/s41591-018-0327-9.","journal-title":"Nat Med"},{"issue":"10","key":"10587_CR110","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nmeth.4430","volume":"14","author":"Y Nihongaki","year":"2017","unstructured":"Nihongaki Y, Furuhata Y, Otabe T, et al. Crispr-cas9-based photoactivatable transcription systems to induce neuronal differentiation. Nat Methods. 2017;14(10):963\u20136. https:\/\/doi.org\/10.1038\/nmeth.4430.","journal-title":"Nat Methods"},{"issue":"12","key":"10587_CR111","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","volume":"20","author":"N Merienne","year":"2017","unstructured":"Merienne N, Vachey G, de Longprez L, et al. The self-inactivating kamicas9 system for the editing of cns disease genes. Cell Rep. 2017;20(12):2980\u201391. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.075.","journal-title":"Cell Rep"},{"issue":"6268","key":"10587_CR112","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered cas9 nucleases with improved specificity. Science. 2016;351(6268):84\u20138. https:\/\/doi.org\/10.1126\/science.aad5227.","journal-title":"Science"},{"issue":"7587","key":"10587_CR113","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity crispr-cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490\u20135. https:\/\/doi.org\/10.1038\/nature16526.","journal-title":"Nature"},{"issue":"21","key":"10587_CR114","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/bioinformatics\/btw476","volume":"32","author":"J Ma","year":"2016","unstructured":"Ma J, K\u00f6ster J, Qin Q, et al. Crispr-do for genome-wide crispr design and optimization. Bioinformatics. 2016;32(21):3336\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btw476.","journal-title":"Bioinformatics"},{"issue":"1","key":"10587_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-1012-2","volume":"17","author":"M Haeussler","year":"2016","unstructured":"Haeussler M, Sch\u00f6nig K, Eckert H, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide rna selection tool crispor. Genome Biol. 2016;17(1):1\u201312. https:\/\/doi.org\/10.1186\/s13059-016-1012-2.","journal-title":"Genome Biol"},{"issue":"2","key":"10587_CR116","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.devcel.2018.04.021","volume":"41","author":"X Yao","year":"2017","unstructured":"Yao X, Zhang M, Wang X, et al. Tild-crispr allows for efficient and precise gene knockin in mouse and human cells. Developmental Cell. 2017;41(2):179\u201384. https:\/\/doi.org\/10.1016\/j.devcel.2018.04.021.","journal-title":"Developmental Cell"},{"issue":"1","key":"10587_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15058","volume":"8","author":"WX Yan","year":"2017","unstructured":"Yan WX, Mirzazadeh R, Garnerone S, et al. Bliss is a versatile and quantitative method for genome-wide profiling of dna double-strand breaks. Nat Commun. 2017;8(1):1\u20139. https:\/\/doi.org\/10.1038\/ncomms15058.","journal-title":"Nat Commun"},{"issue":"33","key":"10587_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201902575","volume":"31","author":"J Liu","year":"2019","unstructured":"Liu J, Chang J, Jiang Y, et al. Fast and efficient crispr\/cas9 genome editing in vivo enabled by bioreducible lipid and messenger rna nanoparticles. Adv Mater. 2019;31(33): e1902575. https:\/\/doi.org\/10.1002\/adma.201902575.","journal-title":"Adv Mater"},{"issue":"8","key":"10587_CR119","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","volume":"27","author":"AM Moreno","year":"2018","unstructured":"Moreno AM, Fu X, Zhu J, et al. In situ gene therapy via aav-crispr-cas9-mediated targeted gene regulation. Mol Ther. 2018;27(8):1818\u201327. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.017.","journal-title":"Mol Ther"},{"issue":"2","key":"10587_CR120","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1021\/acsomega.2c05583","volume":"8","author":"S Bhattacharya","year":"2022","unstructured":"Bhattacharya S, Satpati P. Insights into the mechanism of crispr\/cas9-based genome editing from molecular dynamics simulations. ACS Omega. 2022;8(2):1817\u201337. https:\/\/doi.org\/10.1021\/acsomega.2c05583.","journal-title":"ACS Omega"},{"issue":"7","key":"10587_CR121","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","volume":"52","author":"OM Enache","year":"2020","unstructured":"Enache OM, Rendo V, Abdusamad M, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52(7):662\u20138. https:\/\/doi.org\/10.1038\/s41588-020-0623-4.","journal-title":"Nat Genet"},{"issue":"1","key":"10587_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13073-017-0475-4","volume":"9","author":"D Nicol","year":"2017","unstructured":"Nicol D, Eckstein L, Morrison M, et al. Key challenges in bringing crispr-mediated somatic cell therapy into the clinic. Genome Med. 2017;9(1):85. https:\/\/doi.org\/10.1186\/s13073-017-0475-4.","journal-title":"Genome Med"},{"issue":"4","key":"10587_CR123","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57869","volume":"16","author":"M Asif","year":"2024","unstructured":"Asif M, Khan WJ, Aslam S, et al. The use of crispr-cas9 genetic technology in cardiovascular disease: A comprehensive review of current progress and future prospective. Cureus. 2024;16(4): e57869. https:\/\/doi.org\/10.7759\/cureus.57869.","journal-title":"Cureus"},{"key":"10587_CR124","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/crispr.2017.0013","volume":"1","author":"JS Sherkow","year":"2018","unstructured":"Sherkow JS. The crispr patent landscape: Past, present, and future. The CRISPR Journal. 2018;1:5\u20139. https:\/\/doi.org\/10.1089\/crispr.2017.0013.","journal-title":"The CRISPR Journal"},{"key":"10587_CR125","unstructured":"EMA. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf"},{"key":"10587_CR126","doi-asserted-by":"publisher","unstructured":"Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide - identification of problems and overcoming obstacles. Trans Med Commun. 2019;4:18. https:\/\/doi.org\/10.1186\/s41231-019-0050-7.","DOI":"10.1186\/s41231-019-0050-7"},{"issue":"5","key":"10587_CR127","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455\u201364. https:\/\/doi.org\/10.1056\/NEJMra1706910.","journal-title":"N Engl J Med"},{"issue":"1","key":"10587_CR128","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1353\/pbm.2019.0003","volume":"62","author":"CB Cohen","year":"2019","unstructured":"Cohen CB. Ethical issues in crispr gene editing. Perspect Biol Med. 2019;62(1):47\u201360. https:\/\/doi.org\/10.1353\/pbm.2019.0003.","journal-title":"Perspect Biol Med"},{"issue":"7747","key":"10587_CR129","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/d41586-019-00726-5","volume":"567","author":"ES Lander","year":"2019","unstructured":"Lander ES, Baylis F, Zhang F, et al. Adopt a moratorium on heritable genome editing. Nature. 2019;567(7747):165\u20138. https:\/\/doi.org\/10.1038\/d41586-019-00726-5.","journal-title":"Nature"},{"key":"10587_CR130","unstructured":"Baylis F. Human genome editing: Our future belongs to all of us. Issues Sci Technol 2019;35(3):42\u201344. https:\/\/issues.org\/our-future-belongs-to-all-of-us\/"},{"key":"10587_CR131","unstructured":"Karunarathna I, Hapuarachchi T, Ekanayake U, et al. The ethics of genetic editing: Navigating the future of science 2024"},{"key":"10587_CR132","doi-asserted-by":"publisher","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, et al. Crispr-engineered t cells in patients with refractory cancer. Science 2020;367(6481):eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365","DOI":"10.1126\/science.aba7365"},{"issue":"2","key":"10587_CR133","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/crispr.2017.0024","volume":"1","author":"C Brokowski","year":"2018","unstructured":"Brokowski C. Do crispr germline ethics statements cut it? The CRISPR Journal. 2018;1(2):115\u201325. https:\/\/doi.org\/10.1089\/crispr.2017.0024.","journal-title":"The CRISPR Journal"},{"key":"10587_CR134","doi-asserted-by":"crossref","unstructured":"Greely HT. CRISPR People: The Science and Ethics of Editing Humans. MIT Press 2021","DOI":"10.7551\/mitpress\/13492.001.0001"},{"key":"10587_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.657981","volume":"12","author":"LU Gonzalez-Avila","year":"2021","unstructured":"Gonzalez-Avila LU, Vega-L\u00f3pez JM, Pelcastre-Rodr\u00edguez LI, et al. The challenge of crispr-cas toward bioethics. Front Microbiol. 2021;12: 657981. https:\/\/doi.org\/10.3389\/fmicb.2021.657981.","journal-title":"Front Microbiol"},{"key":"10587_CR136","doi-asserted-by":"publisher","unstructured":"Ridgway A, Agbanyo F, Wang J, et al. Regulatory oversight of cell and gene therapy products in canada. In: Advances in experimental medicine and biology, vol 871. Springer, pp 49\u201371, 2015.https:\/\/doi.org\/10.1007\/978-3-319-18618-4_3","DOI":"10.1007\/978-3-319-18618-4_3"},{"issue":"6","key":"10587_CR137","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","volume":"16","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge R, Anthony E, Barker RA, et al. Isscr guidelines for stem cell research and clinical translation: The 2021 update. Stem Cell Reports. 2021;16(6):1398\u2013408. https:\/\/doi.org\/10.1016\/j.stemcr.2021.05.012.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"10587_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-019-0319-5","volume":"5","author":"M Morrison","year":"2019","unstructured":"Morrison M, de Saille S. Crispr in context: Towards a socially responsible debate on embryo editing. Palgrave Communications. 2019;5(1):1\u20139. https:\/\/doi.org\/10.1057\/s41599-019-0319-5.","journal-title":"Palgrave Communications"},{"key":"10587_CR139","unstructured":"World Health Organization. Who issues new recommendations on human genome editing for the advancement of public health. 2021 https:\/\/www.who.int\/news\/item\/12-07-2021-who-issues-new-recommendations-on-human-genome-editing-for-the-advancement-of-public-health, accessed: 30 Oct 2024"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-024-10587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-024-10587-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-024-10587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:48:31Z","timestamp":1746521311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-024-10587-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":139,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10587"],"URL":"https:\/\/doi.org\/10.1007\/s12265-024-10587-7","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. The authors have no financial or proprietary interests in any material discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"No human or animal studies were carried out by the authors for this review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No informed consent was needed for this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}